Discovery & Development Europe 2026
.png)
Estrel Congress Centre, Berlin, Germany
.png?width=470&height=151&name=Formulation%20%26%20Delivery%20Europe%202026%20Updated%20(Light).png "Formulation & Delivery Europe 2026 Updated (Light)")
Solution Provider Presentation
Solution Provider PresentationA Novel OncoLytic Peptide platform - Immunogenic Cell Death initiation for Immune Cell Recruitment
Industry Presentation• Novel Oncolytic Peptide therapies for hard to treat cancers
• Membrane-Lytic Peptides and immunogenic cell death
• Reprogramming the local tumour microenvironment for systemic response
Unlocking Non Traditional Delivery Routes For Small Molecule Therapeutics
Industry Presentation• Why intranasal delivery is compelling for small molecules
• Formulation and device considerations unique to intranasal products
• Development, safety, and translational challenges
Small Molecule Formulations & Dosage Form With Patient Friendly Delivery Considerations
Industry Presentation• Considerations for Patient-Centric Product Development
• Acceleration Strategies for Small Molecule Development
• Trade-off considerations: “Right first time” vs “Fast to patients”
Oligonucleotide Delivery & Utilising sRNA Delivery Methods In Alternative Modalities
KeynoteSolution Provider Presentation
Solution Provider PresentationSeparation Of PS Diastereomers In GalNAc-Conjugated siRNA By IP‑RP, AEX & HILIC
Industry PresentationThe utility of ion-pair reversed-phase (IP-RP), anion exchange (AEX), and hydrophilic interaction liquid chromatography (HILIC) methods is assessed for phosphorothioate (PS) diastereomer-pair separation.
The determination of diastereomeric composition in the antisense strand of an siRNA is demonstrated.
The deliberate change of the diastereomeric composition could be made detectable.
In manufactured batches of the same sequence comparable diastereomer is demonstrated.
Opportunities And Challenges In Developing And Manufacturing Radiopharmaceuticals
Industry Presentation• Expanding theranostic applications
• Complex manufacturing, isotope supply constraints, and short half-life logistics
• Regulatory hurdles, GMP compliance, and specialised infrastructure requirements
Brain-Targeted Drug Delivery For Neurodegenerative Therapies
Panel DiscussionRecent technological advancements & platforms
Non-viral platforms
Brain-shuttles
Predicting Future Successes: What Is Next for Modalities in CNS Diseases?
Clinically relevant biomarkers and new in-vitro assays
Overcoming Scientific And Technological Challenges Of Formulating Oral GLP-1 Therapies
Panel DiscussionThis panel will explore the scientific and technological challenges of formulating oral GLP-1 therapies, including absorption enhancement, stability, bioavailability, and patient-centric design
• Formulation strategies
• Emerging delivery platforms
• Blood Brain Barrier challenges
• Translational hurdles
• Future directions shaping next-generation oral peptide therapeutics
Exploring Alternative Routes Of Administration For Biologics Beyond IV
Roundtable DiscussionLiposomal Formulation Development: Safety And Efficacy Assessment
Industry PresentationHow Innovations Are Driving The Field Of Drug Delivery?
KeynoteThe presentation will discuss the challenges and opportunities in formulating biologics. In particular, it will focus on the use of ionic liquids to address bioavailability and solubility challenges in high-concentration subcutaneous biologics. It will also cover how effective ex vivo assessment models can accelerate formulation discovery and development.
Physicochemical Constraints And Opportunities In Oral Peptide Development
Industry PresentationpH Gradient Driven Loading Of Anticancer Drug Into Niosomes With Bromocresol Green As A Visual Indicator
Industry Presentation• Studying the effect of different co-surfactants on stabilising the niosomal membrane
• Investigating the influence of niosomes' compositions on formation of a pH gradient
• Visualisation of pH gradients via pH indicator bromocresol green (BCG) as a novel encapsulated model molecule to visually investigate the ability of niosomes to entrap drugs through active loading
• Application of the most optimised BCG niosomal formulation to encapsulate a therapeutic anticancer drug molecule via pH gradient active loading
NAMS Approaches For Ethical Drug Development
Roundtable Discussion• Non-animal based in vitro models for efficacy
• Digital twin approaches for in silico clinical screening
siRNA Therapies Utilising Lipid Nanoparticles
Industry PresentationCell & Gene Delivery Platforms & Technologies
Industry PresentationFormulating Next-Gen Biotherapeutics: Strategies To Enhance Stability, Quality, And Scalability
Panel Discussion• Stabilising complex modalities
• Evaluating non-traditional formulation strategies — including lyophilisation, co-formulation, microencapsulation, or amorphous systems
Delivery of Biologics for Ophthalmology to the Anterior and Posterior of the Eye.
Industry PresentationRetention and delivery of biologics to the anterior and posterior of the eye remains challenging due to ocular anatomy. Topical application of a hydrocolloidal formulation achieves therapeutic delivery of anti-VEGF to the eye posterior, potentially overcoming the need for needle-based delivery. Additional applications and possible mechanisms will be discussed.
From Molecule To Mouth: The Innovation Behind Oral GLP‑1
Industry Presentation• Key scientific breakthroughs enabling oral GLP‑1 (enhancers, formulation, devices)
• Translational challenges and clinical proof-of-concept
• Next-generation strategies for improving efficacy and scalability
Solution Provider Presentation
Solution Provider PresentationEx-Vivo Platform Development For Topical Treatments
Industry PresentationSolution Provider Presentation
Solution Provider PresentationIntermolecular Binding studied with Microfluidic Modulation Spectroscopy (MMS)
Solution Provider PresentationThis presentation explores intermolecular binding interactions using Microfluidic Modulation Spectroscopy, highlighting how molecular-level binding insights drive modern biopharma and accelerate protein, peptide, and RNA drug development at scale now
Solution Provider Presentation
Solution Provider PresentationFrom Expert Silos To Enterprise Capabilities: Democratising Modeling & Simulation In Pharmaceutical Development
Industry Presentation• Democratisation of M&S: From expert tools to self-service simulation app
• Empowering formulation scientists with validated first-principle models
• Enabling virtual experiments before lab work to accelerate development
Data- and AI-driven Development of Lipid Nanoparticles for Targeted mRNA Delivery
Industry PresentationOur mission is to develop high-performing lipid nanoparticles for delivering therapeutics and vaccines. I will discuss our digital-first approach to designing novel ionizable lipids, optimizing formulations, and planning experiments to meet customer needs, with a focus on molecular modeling and integrated high-throughput experimentation in our labs.
Regulatory Landscape Of Smart Devices
Industry PresentationPeptide Delivery Reimagined: Navigating Challenges And Seizing Opportunities For Oral Delivery
Industry Presentation• Challenges of GLP-1 formulations ensuring stability, permeability, solubility enhancement and overall effectiveness of the final product
• Key formulation strategy to enhance oral administration of peptides
Formulation Development and Delivery of Novel Bi-specifics
Industry PresentationImmTAX biotherapeutics redirect T cells to target disease-specific antigens with high potency and specificity. This presentation outlines their mechanism of action and our formulation development strategy, emphasising early optimisation of physical, colloidal and chemical stability. We discuss trade-offs and demonstrate how ultra-low dose requirements are enabled through IV dilution workflows.
Prediction Of Longterm Stability Of Monoclonal Antibodies Using Innovative Biophysical And Data Science Tools
Industry Presentation• Advanced biophysical characterisation to understand degradation pathways and stability risks
• Integration of data science and predictive modelling to forecast long-term stability
• Accelerating developability assessment and formulation decision-making through in-silico insights
Stopping Nitrosamine Formation in Crystalline Drug Products
Industry Presentation• Crystal defects have been shown as the primary cause of nitrosamine formation in ranitidine hydrochloride
• Recrystallisation of ranitidine hydrochloride can essentially stop the formation of nitrosamines on storage by eliminating crystal defects
• This technology can be used in conjunction with traditional nitrosamine-reducing approaches to further mitigate nitrosamine formation for all crystalline drugs
From Amorphous To Manufacturable: Precipitation And Continuous Processing
Industry Presentation• Direct precipitation was selected to allow production of manageable Drug Substance (DS) amorphous
• Continuous DS processing implemented although scale-up and materials challenges resulted in the need for a mitigation plan
• Aiming to strengthened DS–Drug Product interface by generating consistent physical attributes
Strategies For High-Concentration Subcutaneous Antibody Therapeutics
Industry Presentation• Challenges and opportunities in developing high-dose antibody formulations suitable for subcutaneous administration
• Overview of innovative formulation and delivery approaches for high-concentration biologics
• Key considerations related to manufacturability, scalability, and regulatory expectations for next-generation antibody therapeutics
Formulation Development For Established & Emerging Modalities
Industry PresentationSolution Provider Presentation
Solution Provider PresentationSolution Provider Presentation
Solution Provider PresentationJekyll, Hyde, and the Molecule in Between: A Formulation Mystery Solved Early
Solution Provider PresentationDrug development can feel like detective work – especially when a molecule changes character unexpectedly. Through the lens of Dr Jekyll and Mr Hyde, this session uncovers the clues hidden in solubility, stability, and solid state behaviour that only strong preformulation practice can reveal. Come for the literary twist; stay for the science that saves programs time, cost, and complexity.
Using Dissolution-Permeation Assays to Understand Various Aspects of Oral Drug Absorption
Solution Provider PresentationAchieving effective absorption and therapeutic efficacy is critical for the success of oral small molecule drugs. To optimize performance, a deep understanding of key biopharmaceutic properties—such as solubility, dissolution, and membrane permeability—is essential, as these parameters directly impact bioavailability and clinical outcomes.
This session will present innovative in-vitro methodologies designed to enhance developability assessments of small molecules and emphasis will be placed on dynamic dissolution and absorption models, which, when integrated with mechanistic modeling, provide valuable insights into rate-limiting steps in oral absorption. Selected case studies will illustrate the impact of food on oral drug absorption, the possible benefits of using nanoparticle formulations, and the impact of dose level on altering the mechanism for oral absorption when comparing pre-clinical to clinical outcome.
Phosphodiesterase inhibition's effect on oral bioavailability of acylated peptides in conjunction with SNAC
Industry Presentation• Introduction to enhancer based delivery of macromolecules
• Our hypothesis around PDE inhibitors for improving bioavailability of oral peptides
• In vitro selection of formulations
• Preclinical in vivo testing and selection of lead formulation
• Clinical testing of the lead formulations
Solution Provider Presentation
Solution Provider PresentationSolution Provider Presentation
Solution Provider PresentationSolution Provider Presentation
Solution Provider PresentationSPOT On - Boosting Targeted Lipid Nanoparticles Via Site-Specific Conjugation Strategy
Industry PresentationNext Gen Drug Delivery at MERCK KGaA developed a unique system for activation and subsequent immobilization of binders at LNP surface for cell specific oligonucleotide delivery. This Site-specific Protein Optimization for Targeting (SPOT^TM) technology allows for the generation of LNPs with outstanding targeting and transfection efficiency in vitro and in vivo.
Closed-Door Panel Discussion: Delivering Therapeutics That Work – From Modality To Patient
Panel Discussion• Designing for delivery early: integrating molecule, modality, and delivery strategy from preclinical stages
• Route of administration as a strategic lever: choosing and optimising IV, SC, oral, and emerging routes for real-world use
• Breaking delivery barriers: tackling stability, bioavailability, targeting, and manufacturability challenges
• From innovation to implementation: which delivery technologies (AI, automation, digital tools) are truly improving clinical and commercial outcomes
Using Untargeted Multi-Omics Methods To Improve siRNA Safety And Specificity
Industry PresentationThe Landscape & General Concepts Of Oral Delivery Of Peptides
Industry Presentation• Definition of oral biologics and delivery challenges
• Clinical and market landscape: a peptide-dominated reality
• Key biopharmaceutical barriers: stability and permeability
• Enabling technologies for oral peptide delivery
• Clinical case studies and lessons learned
• Strategic implications and future outlook
Predictive Stability Of Glycoconjugate Vaccine Using Advanced Kinetics Modeling And High-Throughput Screening
Industry PresentationIntegrating high-throughput screening with advanced kinetics modeling enables efficient, robust predictive stability modeling for glycoconjugate vaccines and this can be applied to other modalities as well. This approach uses minimal (analytical) resources, with high correlation between rapid assays and traditional methods, supporting accelerated drug product development when long-term data are scarce.
Seeing The Unseen: Advanced Characterisation Of Spray Dried Powders
Industry PresentationThis presentation explores how modern analytical techniques move beyond traditional bulk measurements to reveal individual particle properties. Through real case studies, it is shown how morphology, wall thickness, and particle level distributions provide deeper insight into spray dried and tabletted materials, enabling better formulation decisions, process understanding, and performance prediction.
1. In your experience, where have bulk powder properties been sufficient for decision‑making—and where have they clearly failed to predict clinical or manufacturability performance?
2. Which individual particle attribute do you believe most strongly impacts downstream pharmaceutical performance: morphology, internal structure, or particle‑to‑particle variability—and why?
Integration Of Advanced Kinetics Modeling Tool (AKM) In The Optimisation Of Bispecific Antibody Formulation Development
Industry PresentationIt is particularly important for biopharmaceutical companies developing and distributing fragile biomolecules to ensure the stability and activity of their products during long-term storage and shipment. In accordance with quality by design (QbD) principles, advanced kinetic modelling (AKM) has been successfully used to predict long-term product shelf-life, relying on Arrhenius-based kinetic models built from data generated in short-term accelerated stability studies.
In the case presented, AKM was used to support formulation selection. AKM predicted 3-year HMWs formation for the bispecific using only 6-month stability data on several prototypes.
This predictive approach allowed us to make the best-informed decision on the maximal concentration for commercial formulation lock in a context of significant aggregation compound.
Keeping Up With The Evolving Drug Delivery Landscape, Looking To The Future & Beyond
KeynoteCombination Products in the drug delivery has been evolving over time with traditional and more advanced delivery modalities adapting to treating patient’s needs. We will explore this evolution, highlight some advancements in drug delivery modalities and look at the changing landscape.
• Exploring the foundation of combination products
• Reviewing the evolving landscape and advancements in drug delivery
• Highlighting non-traditional routes of administration
Cracking The Toughest Formulation & Delivery Challenges In Advanced Modalities
Panel Discussion• What makes advanced therapeutic modalities inherently difficult to formulate and deliver?
• Overcoming key biological barriers: stability, targeting, immunogenicity, and intracellular delivery
• Case studies across diverse modalities:
o Cell & gene therapies; ADCs; biologics and emerging complex modalities
• Lessons learned from clinical successes and setbacks across modalities
• Where current formulation and delivery strategies are still falling short—and what’s needed next
Towards Digital Twins In The Development Of Small Molecule Pharmaceutical Processes
Roundtable Discussion• Multiphysics-based models
• AI/ML-based models
• Synchronisation with the physical counterpart
Multiphysics Simulations Combined With Physics Informed Neural Networks (PINNs) In The Development Of Pharmaceutical Processes
Industry PresentationMultiphysics simulations are highly effective for developing pharmaceutical processes, but their computational cost limits scalability. Physics-Informed Neural Networks (PINNs), trained on multiphysics simulation data, can retain comparable detail and complexity while being far less computationally intensive, enabling faster development and highly scalable process modeling.
Improving Delivery Of Antibody–Oligo Conjugates With Endosomal Escape Capabilties
Industry PresentationFor large emerging modalities such as antibody–oligonucleotide conjugates with intracellular targets, efficacy is constrained not by tissue distribution or cellular uptake, but by intracellular availability at the site of action. We present an approach enabling productive intracellular delivery, linking exposure, cellular uptake, and endosomal escape to on-target delivery and functional target engagement, reframing delivery as the key determinant of pharmacological activity.
Announcement of Young Scientist Poster Presentation Awards by ELRIG & Start of Wine Tasting Activities
Morning Break & Refreshments
Morning Break & Refreshments
The Automation & AI Landscape In 2026
KeynoteThe phrase “Lab-in-the-loop” is an often-used term. But what does it really mean? How far along are we on our journey towards autonomous science?
This presentation will focus on how Recursion is operating at the interface between the physical world and the virtual world. In particular, the infrastructure required to enable agentic orchestration of the AI-driven, iterative, design-make-test and learn testing that refines small molecule therapeutics.
Lunch Break
Afternoon Break & Refreshments
End of Event
Lunch Break
Including Scheduled Demos in the AI & Digitisation Zone by AI Platform Companies
Designing For Impact – Moving Beyond Inhibitors
KeynoteWhat Is Next For Neurodegenerative Diseases
Industry PresentationNeurodegenerative diseases remain one of the most urgent unmet challenges in medicine, marked by rising prevalence and limited disease-modifying treatments. Despite decades of research, progress has been incremental, with many therapies addressing symptoms rather than underlying biology. However, advances in molecular targeting, biomarker-driven diagnosis, and precision delivery are beginning to shift the landscape. The next phase will likely be defined by earlier intervention, combination approaches, and technologies capable of reaching previously inaccessible regions of the brain.
Adventures In Precision Medicine For Cancer: 25 Years After The Genome Sequence
Keynote• Oncology leads the way in genome-based medicine with estimates of at least 90 FDA approvals requiring biomarkers for optimal patient selection – almost half of all drugs authorized since 1998
• In discovery, ‘Drugging the Cancer Genome’ is being further enabled by technologies such as CRISPR, chemical probes, structure/fragment-based design, degraders (PROTACs and molecular glues), immune-targeting and AI/machine learning approaches
• In clinical development, use of the ‘Pharmacological Audit Trail’ framework is being enhanced by cheaper next generation sequencing, liquid biopsy, and innovative PK/PD modelling
Brain Health: A Call For Global Action & Unity
KeynoteXphore For Extrahepatic Delivery Of RNAs
Industry Presentation-xPhore is a peptide based platform amenable to deliver most nucleic acid modalities, including siRNA, mRNA, circRNA and DNA
-xPhore delivers RNA/DNA to sites of inflammation without liver sequestration
-Modularity allows application in different indications
No sessions found matching your filters.